Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured
The model's full reasoning — Q1 2022 call → NOThe question asks whether management lays out a timetable of specific conversions—identified pieces of business already secured or in motion, each with timing attached—so the forward story reads as a schedule of things turning on. Let me examine the transcript for what management says about the next four or so quarters. Key items mentioned: 1. ModeX acquisition - closed today, but this is an acquisition, not a revenue-generating conversion with a timetable. They mention R&D expenses will increase as programs move to clinic over next 18 months, but no revenue timetable. 2. Pfizer milestones - $85 million in milestones from Japan and Germany launches, received in Q2. This is a one-time payment, not a recurring conversion. 3. Somatrogon gross profit share - Japan region starts in Q2 once pricing established; Europe needs two more major markets, projected about a year from initial approvals. This is somewhat vague. 4. Sema4/GeneDx - closed April 29, but this is a divestiture, not a revenue source. 5. BioReference - COVID testing volumes, Scarlet Health, Teladoc relationship, MVP Healthcare collaboration. These are described as ongoing business activities, not scheduled conversions with timing. 6. RAYALDEE - mentioned revenue but no forward timetable. The question asks about "specific conversions—identified pieces of business that are ALREADY SECURED OR ALREADY IN MOTION, each attached to an at-least-approximate time frame in which it starts contributing." Looking at what management actually says: - The $85 million Pfizer milestone is secured and will be received in Q2. That's a one-time event, not a recurring conversion. - The gross profit share from Japan starts in Q2, but they say "we have not forecasted royalty or gross profit share amounts until we develop some actual history throughout 2022." So they're not even forecasting it. - Europe gross profit share is "about a year from initial approvals" - vague and contingent on pricing in additional markets. - ModeX programs are in early development, no revenue timetable. - BioReference activities are ongoing business, not scheduled conversions. The forward guidance is mostly about testing volume assumptions (3-3.5 million COVID tests), cost reductions, and commercial investments. There's no clear timetable of secured business converting to revenue.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.